Thank you for standing by and welcome to the Alnylam Pharmaceuticals Third Quarter 2022 Financial Results Conference Call. As a reminder, today’s conference call is being recorded. I would now like to turn the conference over to the company. Please go ahead.

Good morning. I am Christine Lindenboom, Senior Vice President of Investor Relations and Corporate Communications at Alnylam. With me today on the phone are Yvonne Greenstreet, Chief Executive Officer; Tolga Tanguler, Chief Commercial Officer; Akshay Vaishnaw, President; and Jeff Poulton, Chief Financial Officer. For those of you participating via conference call, the accompanying slides can be accessed by going to the Events section of the Investors page for our website, investors.alnylam.com/events. During today’s call, as outlined on Slide 2, Yvonne will offer introductory remarks and provide some general context. Tolga will provide an update on our global commercial progress, Akshay will review early pipeline updates and clinical progress, and Jeff will review our financials and guidance, followed by a summary of upcoming milestones before we open the call to your questions. I’d like to remind you that this call will contain remarks regarding Alnylam’s future expectations, plans, and prospects, which constitute forward-looking statements for the purposes of the Safe Harbor provision under the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including those discussed in our most recent quarterly report on file with the SEC. In addition, any forward-looking statements represent our views only as of the date of this report and should not be relied upon as representing our views as of any subsequent date. We specifically disclaim any obligation to update such statements. With that, I’d like to turn the call over to Yvonne.

Thanks, Christine, and thank you everyone for joining the call today. We are very pleased with the results delivered in the third quarter, both commercially and with our pipeline. Commercially, this is the first full quarter of our AMVUTTRA launch since the U.S. approval back in June, which drove 30% growth in the U.S. for the TTR franchise compared to quarter two. Clinically, the TTR franchise is also performing well. We presented positive results for the APOLLO-B Phase 3 study of vutrisiran in patients with ATTR amyloidosis with cardiomyopathy, validating the therapeutic hypothesis that RNAi-mediated silencing of TTR has the potential to result in a disease-modifying impact on the cardiac manifestations of ATTR amyloidosis. We are delighted with the totality of these results and we look forward to submitting a supplemental NDA for ONPATTRO by year-end. This also gives us increased confidence in the HELIOS-B Phase 3 outcome study of vutrisiran in ATTR amyloidosis with cardiomyopathy, which is on track for top-line results in early 2024. Our earlier stage programs are advancing as well, with positive results presented from the Phase 2 study of cemdisiran in patients with IgA nephropathy and preliminary data in patients from the ongoing Phase 1 study of ALN-HSD in development for the treatment of NASH. In the coming quarters, we expect to have more exciting updates from our pipeline, including results for the potential biannual dose regimen for vutrisiran, preliminary Phase 1 results in healthy volunteers for ARN XDH, an investigational RNAi therapeutic for the treatment of gout, completion of enrollment in the KARDIA-2 Phase 2 study of zilebesiran, and initiation of a Phase 1 healthy volunteer study of ALN-TTRscO4, for which we filed a CTA earlier this month. This execution aligns with our focus on key drivers for Alnylam’s growth over the next several years. Firstly, the potential near-term expansion of our TTR franchise opportunity, where we aim to become a global leader in delivering impactful and highly differentiated medicines for patients. Secondly, our expansion beyond rare diseases and into prevalent diseases. The third growth driver for the company comes from our sustainable innovation engine comprised of new platform enhancements, opportunities with extrahepatic delivery, and our ability to find new genetically validated targets that can drive further pipeline expansion to 2025 and beyond. We believe all of this positions us well to deliver on our 'Alnylam P. E. A. C. E. it by 2025' goal, making Alnylam a top biotech company, developing and commercializing transformative medicines for rare and prevalent diseases for patients around the world driven by a high-yielding pipeline of first and/or best-in-class product candidates from our organic product engine, all while delivering exceptional financial results. With that, let me now turn the call over to Tolga for a review of our commercial performance.

Thanks, Yvonne and good morning everyone. Q3 was a strong quarter for our commercial portfolio, with 9% quarter-over-quarter growth driven by a strong launch of AMVUTTRA in the U.S., as Yvonne highlighted. While still early, we are encouraged by several signs indicating that AMVUTTRA is expanding the size of the opportunity for our hATTR-PN franchise. I will have more details to share on this shortly. The strengthening of the U.S. dollar continues to impact product revenues from our international operations, as ONPATTRO, GIVLAARI, and OXLUMO Q3 product sales each experienced FX headwinds compared with the prior quarter and prior year periods. With initial sales of AMVUTTRA now reflected in our quarterly financial results, we will highlight our results for ONPATTRO and AMVUTTRA on a combined franchise basis moving forward. We saw robust growth in our TTR franchise in Q3, achieving $170 million in global net product revenues for ONPATTRO and AMVUTTRA, representing an 11% increase compared with the second quarter and a solid 41% growth compared with Q3 2021. At the end of Q3, over 2,580 patients were on commercial ONPATTRO or AMVUTTRA treatment worldwide, up from over 2,400 patients at the end of the second quarter, representing a steady 8% quarterly patient growth. In the U.S., combined sales of ONPATTRO and AMVUTTRA increased a robust 30% versus the second quarter, primarily impacted by a 19% increase in demand growth, driven by the strength of initial AMVUTTRA patient uptake, which more than offset the decrease in patients on ONPATTRO that switched to AMVUTTRA. In total for the quarter, 180 patients initiated AMVUTTRA treatment, with over 40% representing new patients for Alnylam and the balance representing patients switching from ONPATTRO. Initial AMVUTTRA launch inventory stocking in the distribution channel increased growth by an additional 11% in the quarter. In our international markets, ONPATTRO Q3 product sales decreased 5% versus Q2 2022 despite an increase in patients on therapy as the timing of orders in partner markets and FX headwinds offset the increase. Our global results continue to be challenged by foreign exchange headwinds, with ONPATTRO year-over-year reported growth of 41%, held back 11 percentage points due to the foreign exchange impact of the strengthening U.S. dollar. Now, I’d like to provide you with some additional color on our AMVUTTRA U.S. launch. In the first 4 months of launch, new patient start forms have doubled to an average of 60 start forms per month, excluding switches in comparison to 30 start forms per month for ONPATTRO in the first half of this year, which we believe highlights the strength of the AMVUTTRA launch to date. Our demand generation has been healthy and balanced between community accounts and centers of excellence, while about 17% of start forms have been generated from new prescribers. We are seeing our patient base broaden to include a variety of newly and previously diagnosed patients starting on AMVUTTRA, with significant enthusiasm being expressed for AMVUTTRA’s product profile, including quarterly subcutaneous dosing. Meanwhile, on the access front, given our parity pricing to date, we have not encountered any significant access headwinds and have made significant progress with formulary approvals, providing smooth access to patients who are put on AMVUTTRA therapy. Additionally, we are pleased with the average time from receipt of start forms to initiation of therapy for AMVUTTRA patients, which is already in line with our ONPATTRO benchmark. To wrap up with AMVUTTRA, we are also excited about the recent regulatory approvals in the EU and Japan for hATTR amyloidosis patients with polyneuropathy, and we look forward to launches in Germany and Japan in the fourth quarter. Moving to our AMVUTTRA rare disease franchise, first GIVLAARI, we achieved $46 million in global net product revenues in the second quarter, representing a 1% increase compared with Q2 2022 and 43% growth versus Q3 2021. At the end of Q3, over 460 patients were on commercial GIVLAARI treatment worldwide, up from over 420 at the end of the second quarter, representing 10% quarterly patient growth. In the U.S., sales of GIVLAARI increased 5% versus the second quarter, primarily due to demand growth of 7%, driven by an increase in patients on therapy, which was modestly offset by changes in inventory, stocking, and gross to net sales deductions. In our international markets, GIVLAARI sales decreased 6% compared with the second quarter, with growth in patients on therapy more than offset by lower net pricing and FX headwinds. Finally, the reported 43% increase in year-over-year global net product revenue growth of GIVLAARI was held back 7 percentage points due to unfavorable movements in foreign exchange rates. Moving now to our second ultra-rare disease product, OXLUMO, we achieved $16 million in global net product revenues in Q3, representing a 10% increase compared with the second quarter. At the end of Q3, over 230 patients were on commercial OXLUMO treatment worldwide, up from over 200 at the end of the second quarter, representing 15% quarterly patient growth. In the U.S., sales of OXLUMO decreased 10% versus the second quarter as growth in patients on therapy was more than offset by decreased average patient utilization during the quarter, driven by fewer patients on the monthly loading dose portion of their initial treatment. In our international business, sales of OXLUMO increased 29% compared with the second quarter due to an increase in patients on therapy and higher net realized price during the quarter, partially offset by FX headwinds. Additionally, as with ONPATTRO and GIVLAARI, changes in foreign exchange rates also negatively impacted OXLUMO Q3 2022 results, with reported year-over-year growth of 10% held back by 10 percentage points due to the strengthening U.S. dollar. In conclusion, we are pleased with the growth in revenues and patient demand achieved in Q3 and particularly with early signs of strong performance associated with the AMVUTTRA launch, which we believe represents an important therapy option for hATTR amyloidosis patients with polyneuropathy and an accelerated growth opportunity for our TTR franchise. With that, I will now turn it over to Akshay to review our recent R&D pipeline progress.

Thanks, Tolga and good morning everyone. I will start with our efforts in ATTR amyloidosis, where we are advancing two clinical stage product candidates, Patisiran and Vutrisiran. While ONPATTRO is currently approved in multiple markets around the world to treat the polyneuropathy associated with hereditary ATTR amyloidosis, we are committed to expanding the product’s label for the treatment of cardiomyopathy in both hereditary and wild-type ATTR amyloidosis patients. To this end, we are excited to have recently presented positive results from the APOLLO-B Phase 3 study, where Patisiran achieved a statistically significant and clinically meaningful improvement relative to placebo in the 6-minute walk test at 12 months, the primary endpoint of the study. It also achieved a statistically significant and clinically meaningful improvement relative to placebo at 12 months on the Kansas City Cardiomyopathy Questionnaire, which is the study’s first secondary endpoint and a key measure of patient self-reported health status and quality of life. Furthermore, Patisiran demonstrated an acceptable tolerability profile, and we are very encouraged by the overall safety profile of Patisiran. Collectively, we believe these efficacy results validate the therapeutic hypothesis that RNAi-mediated silencing of TTR has the potential to result in a disease-modifying impact on cardiac manifestations of ATTR amyloidosis. With these results in hand, we remain on track to submit a supplemental NDA filing for review by the FDA by the end of this year, with the goal of obtaining regulatory approval in the U.S. and making this medicine available to patients with ATTR amyloidosis with cardiomyopathy as rapidly as possible. We are also advancing Vutrisiran, which is delivered by a quarterly subcutaneous injection and among its benefits is AMVUTTRA to treat the polyneuropathy of hereditary ATTR amyloidosis. AMVUTTRA was approved based on results from the HELIOS-A Phase 3 study, which includes an ongoing randomized treatment expansion where we are evaluating a biannual dosing regimen, and we are on track to share results in late 2022. As with ONPATTRO, year two, we are committed to expanding the label to include the treatment of cardiomyopathy in hereditary and wild-type ATTR amyloidosis patients. This is being accomplished by the HELIOS-B Phase 3 study of investigational Vutrisiran. HELIOS-B, which is fully enrolled, has an endpoint of all-cause mortality and CV events assessed after at least 30 and up to 36 months, and we are on track to share top-line results in early 2024. As was announced this morning, after clinical consideration, we have made the decision not to conduct the optional interim analysis for HELIOS-B. Several factors drove us to this decision, including the early completion of enrollment of HELIOS-B, which meant that any potential acceleration in the approval based on an interim analysis was minimal relative to waiting until the readout from the fully completed study in early 2024. Our desire to conclude HELIOS-B with the strongest possible dataset, including outcomes data; and further enhancement in confidence in HELIOS-B with the recently positive APOLLO-B readout. As such, we look forward to the HELIOS-B readout as scheduled early in 2024. We have also announced this morning that while we remain very excited about the opportunity for TTR lowering to address Stargardt disease, we do not plan to initiate a Phase 3 study of Vutrisiran this year as previously planned as we evaluate the impact of the Inflation Reduction Act on therapies being developed for orphan diseases. We are continuing to consider options for the best path forward in Stargardt disease as we recognize the significant unmet medical need in this patient population. Lastly, regarding our TTR franchise, we are excited to announce that a clinical trial application has been filed for ALN-TTRsc04, the first clinical program from our IKARIA platform, which aims to achieve an annual dosing regimen with highly potent and reversible effects. We expect to initiate a Phase 1 study in healthy volunteers by year-end. In addition to our late-stage clinical programs, we believe we have also been making great progress with our early and mid-stage programs. A notable highlight this quarter was our announcement of positive results from our Phase 2 study of zilebesiran, an investigational RNAi therapeutic targeting the C5 competitive complement pathway, which is in development in collaboration with Regeneron for the treatment of IgA nephropathy or IgAN. In the study, at week 32, treatment of cemdisiran resulted in a 37% mean reduction in baseline in the 24-hour urinary protein to creatinine ratio relative to placebo, which is the primary readout of the study and an important prognostic marker of disease progression. The results of secondary endpoints were also consistent with the therapeutic benefit of cemdisiran in IgAN. There were no significant drug-related safety signals, and we believe these collective efficacy and safety data support continued clinical development of cemdisiran monotherapy in patients with IgAN. We look forward to gaining alignment with Regeneron to finalize plans for Phase 3 and sharing those updates with you in due course. Another exciting highlight recently was the announcement of the preliminary Phase 1 data supporting the clinical advancement of ALN-HSD, an investigational RNAi therapeutic targeting HSD17B13 in development for the treatment of nonalcoholic steatohepatitis or NASH. After single-dose evaluation in healthy adult volunteers, on multiple doses of ALN-HSD are being studied in adult patients with NASH. In the first two Part B cohorts, namely 200 and 400 milligrams quarterly, have completed at least 6 months on the study. The remaining cohorts are exploring a lower dose or a later biopsy time point. In the first two Part B cohorts, ALN-HSD was associated with robust target knockdown and numerically lower liver enzymes and biopsy-derived non-alcoholic fatty liver disease activity scores over six months in patients receiving ALN-HSD relative to placebo. The study was not powered to achieve statistical significance on these endpoints and the primary outcome measure is frequency of adverse events. ALN-HSD has exhibited an encouraging pace and tolerability profile to date. Based on these results, we plan to initiate a Phase 2 study in adult patients with NASH in late 2022 in collaboration with Regeneron. Now turning to our ALN-APP program, which is in development for the treatment of Alzheimer’s disease and cerebral amyloid angiopathy. ALN-APP is our first investigational conjugate RNA therapeutic targeting gene expression in the central nervous system. We continue to make progress enrolling patients with early onset Alzheimer’s disease and are progressing through the single ascending dose portion of the Phase 1 study. As we announced in our press release this morning, we now expect initial clinical data from this study in early 2023, a slight change from our previous guidance of late 2022. This change reflects the continued progression through dose escalation cohorts at a measured pace and the rigor with which we are screening for appropriate patients for this study that meet all necessary inclusion/exclusion criteria. We believe this initial clinical data with ALN-APP is positive and will be an important milestone for our CNS platform, showing that RNAi can achieve clinically relevant degrees of target knockdown in the CNS with the safety and dosing profile that supports further development. We look forward to reporting top-line results from the study in early 2023. These are just a few highlights from our broad and innovative pipeline driven by our underlying organic product engine that will drive sustainable innovation and represents a key growth driver for Alnylam in the years to come. Representative of the productivity of our engine, we look forward to two further CTR-IND filings for first-in-human studies before year-end, namely ALN-KHK for the treatment of metabolic liver disease, including diabetes, which is an Alnylam wholly owned program, and ALN-APP for NASH in collaboration with Regeneron. We will be discussing all this in greater detail at our upcoming R&D Day being held virtually on December 15, and I encourage you to tune in.

Thanks, Akshay, and good morning, everyone. I’m pleased to be presenting a summary of Alnylam’s Q3 2022 financial results and an update on our full-year guidance. Starting with a summary of our P&L results for Q3 2022. Total product revenues for the quarter were $232 million or 39% growth versus Q3 2021. It is also worth noting that year-over-year growth in combined product revenues was held back by approximately 10% due to the foreign exchange impact of a strengthening U.S. dollar, given that approximately 45% of our product revenues are generated via sales in international markets. Net revenue from collaborations for the third quarter was approximately $29 million, representing a 45% increase compared with Q3 2021, primarily due to an increase in revenue recognized in connection with our collaboration agreement with Regeneron and contributed to an increase in reimbursable activities under our Research Services arrangement in addition to an increase in revenue recognized associated with partnership clinical trial activities. Our non-GAAP R&D expenses increased 6% in the third quarter of 2022 compared to the same period in 2021, primarily due to increased compensation-related expenses as a result of increased employee headcount and an increase in development expenses, primarily associated with the ramp-up in enrollment in the KARDIA-1 and KARDIA-2 zilebesiran Phase 2 studies, offset by decreased clinical batches manufactured during the quarter. Our non-GAAP SG&A expenses increased 33% in the third quarter of 2022 compared to the same period in 2021, primarily due to increased headcount and other strategic investments in support of our AMVUTTRA launch and other corporate purposes. Our non-GAAP operating loss for Q3 2022 was $130 million, representing an $18 million improvement compared with Q3 2021, driven by strong top-line growth, offset by more moderate growth in operating expenses. Finally, we ended the quarter with cash, cash equivalents, and marketable securities of $2.3 billion compared to $2.4 billion at the end of 2021, with the decrease primarily due to our year-to-date operating loss in 2022. This decrease was largely offset by approximately $200 million received from employee option award exercises and approximately $135 million received from the issuance of convertible debt, net of repayment of our Blackstone credit facility, inclusive of prepayment premiums, purchase of cap call transactions, and offering expenses. We continue to believe our current cash balance is sufficient to bridge us to a self-sustainable financial profile. Now I’d like to turn to our full-year 2022 financial guidance. Starting with net product revenues, we continue to anticipate combined net product revenues for our four commercialized products will be between $870 million and $930 million. Additionally, given the continued strengthening of the U.S. dollar since we issued our current guidance in April, we are currently trending towards the lower half of our $870 million to $930 million guidance range. We are reducing our guidance for net revenue from collaborations and royalties from a range of between $175 million and $225 million to a range between $100 million and $150 million, primarily due to the timing of reimbursable activities in our collaboration with Regeneron and lower-than-anticipated Leqvio royalties and sales milestones. Our guidance for combined non-GAAP R&D and SG&A expenses remains unchanged and is a range between $1.390 billion and $1.450 billion. Let me now turn from financials and discuss some key goals and upcoming milestones on deck through the end of 2022. We will continue executing on our global commercialization of ONPATTRO and AMVUTTRA, GIVLAARI and OXLUMO. Next, our TTR franchise will have important updates. With Patisiran, we plan to submit an sNDA for review by the FDA for the treatment of patients with ATTR amyloidosis with cardiomyopathy. With Vutrisiran, we plan to report results on a biannual dose regimen from HELIOS-A in hATTR amyloidosis patients with polyneuropathy. Lastly, for ALN-TTRsc04, we are on track to initiate a Phase 1 study in healthy volunteers. In our mid- and early-stage portfolio, we are looking forward to milestones that include completion of enrollment in the KARDIA-2 Phase 2 study of zilebesiran at or around year-end, preliminary results expected from healthy volunteers in the Phase 1 study of ALN-XDH in development for patients with gout, and submission of CTA filings for ALN-KHK for the treatment of metabolic liver disease, including diabetes, and ALN-APP for NASH. Let me now turn it back to Christine to coordinate our Q&A session.

Thank you, Jeff. Operator, we will now open the call for your questions.

Thank you. Our first question comes from Maury Raycroft from Jefferies. Your line is open.

Hi. Good morning, and thanks for taking my question. I was wondering if you can talk about whether you’ve received any feedback from the FDA on APOLLO-B data and what the NDA package would contain? Also, could you talk about your confidence around your primary endpoint P value and whether FDA has provided any specific comments on this?

Thanks for that question, Maury. I mean, clearly, we were delighted with the results from our APOLLO-B study, where we delivered clinically meaningful and significant benefits across the 6-minute walk test and KCCQ, which are important measures for patients in terms of how they function and feel, and we’ve got good safety and numerical reduction tests. So we are very confident with the package of data that we have supporting this indication holistically, particularly given the small size and short duration of the study; perhaps you can follow up on our regulatory progress.

Yes. Thanks, Maury, and thanks, Yvonne. I think you addressed at a high level the key positives that came out of the study that reinforces that therapeutics can have a significant impact, we believe, in ATTR amyloidosis, including in the cardiomyopathy. We’re proceeding to file the supplemental NDA by the end of the year, as we’ve said. We’re confident in this package as the file goes under review; the FDA will get a safety update, 180-day safety update during review, so we will be providing that, of course. And we will be very responsive to any questions they have. And so that’s as much as I can say at this point in time. But we’ve shared the data across two meetings at ISA and HFSA and had extremely strong and positive responses from investigators, KOLs, and others. So we are excited for that.

That’s great. So moving forward expeditiously. Thank you, Maury. Next question.

Thank you. Our next question comes from Salveen Richter. Your line is open.

Did the outcomes analysis of APOLLO-B impact your thinking on treated or placebo separation here? And how much time do you save? Thank you.

Actually, I think that’s one for you.

Could you repeat the full question? I think you were talking about the outcomes analysis, but the line is not brilliant, so we didn’t quite catch the second half of your question. Could you repeat it for us?

Sure. Could you explain the factors you considered when deciding not to conduct the HELIOS-B interim? I’m just wondering whether the outcomes analysis of APOLLO-B impacted your thinking on treated placebo separation and how much time you save here?

The question is around thinking behind not progressing the interim analysis.

Yes, I mean, Salveen, as you intimate, the positive data out of APOLLO-B significantly increased our confidence and belief that the design and conduct of HELIOS-B is the right test of the hypothesis that vutrisiran can help patients with ATTR cardiomyopathy. So we feel quite comfortable looking at all the detailed data, most of which we’ve shared already at these international meetings, but there are others. And so that was one major factor. The second was we obviously want to have the best data associated with vutrisiran to make it a best-in-class product, hopefully, for patients with ATTR cardiomyopathy. The best way to do that is to preserve alpha and not mess around with the statistics, which obviously, if you do an interim, then that has a significant downstream conference on the statistics for the final readout in early 2024. And thirdly is just the speed at which everything has moved, which we’re delighted by. The fact that HELIOS-B actually overenrolled means it’s such a narrow time frame between any putative interim and any potential approval thereof versus the full readout in early 2024 and hopefully getting a great label in serving patients with ATTR cardiomyopathy.

That’s great actually. Thank you very much. Next question.

Thank you. Our next question comes from Tazeen Ahmad from Bank of America. Your line is open.

Hi, good morning, guys. Thanks so much for taking my question. Maybe, Yvonne, can you just clarify whether your team has already met with the FDA for your pre-sNDA meeting regarding the APOLLO-B results yet? Or is that still to come? And then secondly, do you have any expectations about whether or not an AdCom would be needed to review this filing? It is the second indication proposed for an already approved drug, but I just wanted to get your latest thoughts on that? Thanks.

Yes, thanks, Tazeen. I mean, as you know, we don’t comment on regulatory interactions. I think I actually covered this in an earlier question. We’re very confident with the package that we have supporting this indication, and we’re moving forward as planned with a submission later this year. That’s about all I can say on the topic. But thanks for the question.

Thank you. Our next question comes from Eliana Merle from UBS. Your line is open.

Hey, thanks so much for taking the question. Just another one in terms of thinking about HELIOS-B as well as the potential uptake in cardiomyopathy. Could you help us understand how you interpret the data in tafamidis combination? And what this could potentially mean in terms of uptake in, say, tafamidis progressors or combination use in the real world commercially? And any initial feedback say you are hearing initially? I know it’s early, but just curious your thoughts.

Right. So I think there may be kind of two parts to the question. I think one actually may be starting off with new perspectives around data in combination with the evidenced therapeutics, maybe talk to give some perspectives on how you see things in the commercial?

Thank you, Yvonne. As per your question, Eliana, regarding the subgroup concomitant with Patisiran. Just to step back, this was a large robust study that considered the real-world population out there. The majority of whom don’t have any drug right now, about 75% of the study was on placebo and no background therapy at about 25% of patients had background therapy. I refer you to our HFSA output and Dr. Mara’s very eloquent discussion of why it’s a little bit of a folly to cut into small subgroup analyses that really are not powered, and the study was not designed to tell we fool ourselves. And again, Dr. Mara explained and discussed all of this very well, I thought it HFSA. So the overall readout of the study, I think, was robust and excellent, impacting patient functionality via the fixed in walk distance and the quality of life, lots of internal consistency in the data. This is a strong package and we’re delighted with it. I appreciate the interest of subgroups, so that’s really not what the study was meant to read out.

Yes, I thought that just generally or factors around how the commercial...

Yes. Just to build on Akshay’s point, it would be premature for us to comment on anything specific without the label. But what we can tell you is if you just look at the numbers since the launch of tafamidis, the diagnosis rate went up by 10x, and we certainly anticipate that to continue. This is a highly devastating disease; across the U.S. and internationally, there are about 250,000 to 300,000 patients suffering from this condition. What we know is there are a lot of untreated patients, and those patients who continue to progress on tafamidis. Therefore, we believe our upcoming therapies, if they are approved, will be a very attractive option for both physicians and obviously for patients.

Thank you. So absolutely lots of medical needs still for these patients, unfortunately. Next question please.

Thank you. Our next question comes from Ritu Baral from Cowen. Your line is open.

Good morning, guys. Thanks for taking the question. Yvonne or Akshay, should we be expecting priority review on the sNDA just given what you and your regulatory consultancy see as the unmet need in TTR cardiomyopathy? And can you just also remind us when the last interaction you had with the FDA was in the past, obviously not forward-looking? If there has been any significant turnover in the review team or senior members in the review division since then.

Thanks, Ritu. So another question about the regulatory outlook here actually in terms of expectations with respect to priority review and another question really just asking us to comment on our progress with regulatory interactions. I think you’ve sort of answered the question, but maybe you can reiterate the point.

Yes. I mean, I think it, thanks for the question. As you know, we don’t discuss the back and forth with regulators. I will reiterate what I said earlier, that we’re confident in this data package, we’re on track to file the supplemental NDA by the end of the year, and the priority review, well, that’s the FDA’s decision, and they have to evaluate the pros and cons of this therapy and the data package we’ve submitted. We will eagerly await their decision, but there is not much more I can add.

And Ritu, as for the review team turnover, I think that’s at the discretion of the FDA's management, and we’re not really in a position to speak to that. Thank you. Next question.

Thank you. Our next question comes from Jessica Fye from JPMorgan. Your line is open.

Hey, guys. Good morning. Thanks for taking my questions. Did you have a pre-NDA meeting yet for the ONPATTRO cardiomyopathy filing or if not, do you expect to?

Yes. Thanks for the question. Again, I think there is lots of interest around this. The most important thing is that we obviously have lots of back and forth with regulators across all our programs. And let me just reiterate that we will file the supplemental NDA by the end of the year for this program based on everything we have discussed so far on this call and in many other settings. So, thanks for the question.

Thanks, Akshay. Next question please.

Thank you. Our next question comes from David Lebowitz from Citi. Your line is open.

Thank you very much for taking my question. When you look at the ONPATTRO, the AMVUTTRA new patient start forms, I noticed that the number of new patients’ percentage uptick from what was announced in the first quarter of launch, I think we went from about a third to nearly 50%. Could you comment on what the expectations for new patients to be coming to market is and what that might – how that might impact growth of the overall franchise relative to what ONPATTRO would have done without the presence of AMVUTTRA?

Yes. No, that’s a great question. I mean we are particularly pleased with the performance of our TTR franchise, especially regarding the progress of the AMVUTTRA launch in the U.S. We are seeing a great dynamic with approximately half of new patients and switches. I think you made the point about a TTR franchise, which I would like to underscore. I think we now really have a TTR franchise, and we expect to be able to grow the PN market and encourage earlier treatment given the very effective regimen of AMVUTTRA. But Tolga, do you want to add some more color maybe to how you are seeing the outlook for the TTR franchise?

No, absolutely, Yvonne. Look, early signs of the U.S. AMVUTTRA launch are a good testament to the overall TTR franchise's future. Our TTR franchise grew by 30% versus last quarter, driven mainly by AMVUTTRA. Two-thirds of this growth was really demand. In our view, early signs of performance really confirm three key beliefs. One is that with fine available treatments, there is a significant unmet need, and the role of AMVUTTRA and its attractive product profile will continue to drive growth. That’s going to be important. We do have the strong foundational capabilities that we built over time across customer-facing capabilities that will allow us to continue expanding this growth. So, we are really excited about this. We are still scratching the surface in terms of diagnosis and treatment. There are 10,000 to 15,000 patients in the U.S. that suffer from this condition. We believe AMVUTTRA’s product profile will be a very nice fit for that treatment regimen.

Thanks, Tolga. Next question please.

Our next question comes from Gena Wang from Barclays. Your line is open.

Thank you for taking my questions. Sorry, I will ask an APOLLO-B question again. I think because there are quite some questions raised on its approvability since it’s only one study and then there is no outcome data. So, maybe if you could refresh our memory on the history of the APOLLO-B study. So, basically, how the study was designed and was it aligned with the FDA?

Yes. Akshay, that’s clearly for you.

Yes. Thanks, Gena. I think we have discussed much of this on other calls, but let me just reiterate, Gena, that this is – I am losing track a little bit—say, the seventh Phase 3 study or seven Phase 3 studies we have negotiated with the FDA and other regulators around the world. All our work is in collaboration with guidance from regulators. We have four Alnylam products approved based on that excellent set of dialogues and the relationships we have and understanding how regulators are guiding us. This product and this trial was no different from that. So, if any credibility or confidence is derived from our prior performance, I would like you to apply it here. Now, in the specifics here, when APOLLO was done, we all remember the conversations, those of you that were involved then, the cardiac data we got a subgroup data from APOLLO were very promising. The FDA said, yes, that is the case, and we have discussed that before. Based on that, they guided us that we should do a separate study in a cardiomyopathy population. With that conversation and collaboration, the design that you see in APOLLO-B resulted. And so this study was done in close collaboration with regulators, and we are grateful for the guidance, and we are very happy with the outcome where clearly, we have shown the impact on patient functionality and quality of life, which are two cornerstones of the FDA’s basis for approval of drugs. Safety looks very encouraging to us, too. And then finally, on the monetary front, you will recall that four patients were on placebo rather than on patisiran and 10 on placebo. So, that’s encouraging, although it’s a small number. We believe this package is quite strong for a trial that was designed in collaboration with regulators. Therefore, we are looking forward to filing the NDA.

Thank you.

Next question.

Thank you. Our next question comes from Paul Matteis from Stifel. Your line is open.

Hey. Thanks so much. I was really interested in your comments in the press release and in the prepared remarks on drug positioning related to the Inflation Reduction Act and broader drug pricing risk. To that point, you just filed a CTA for a once annual TTR knockdown drug. How do you think about positioning that and balancing Stargardt versus this potentially just being a next-gen and TTR cardiomyopathy, and also enabling you to maintain premium pricing beyond a decade in that space? Thanks so much.

Thank you for the question here. The Inflation Reduction Act is a significant shift in Medicare and how the Federal Government regulates our industry. We are supportive of the new Part D patient out-of-pocket caps, but we have considerable concerns about a couple of other aspects of the legislation. Clearly, the first is around concerns that small molecule medicines face negotiated Medicare reimbursement rates only 9 years after approval compared to 13 years for monoclonal antibodies. I think very pertinent to us in the near term is that while the exemptions in the Inflation Reduction Act from Medicare price negotiation for a drug that has a single orphan drug indication, they are now creating this incentive to pursue the approval of drugs in additional indications. We are still digesting the legislation, but as you pointed out, in the meantime, besides the Patisiran Phase 3 study in Stargardt disease, we are considering options for the best path forward. I would like to note three points really: One, we remain excited about the opportunity for an RNAi-mediated TTR lowering method as a potential therapy in patients with Stargardt disease. We think it’s an important unmet medical need. Secondly, I think you touched on it when you talked about TTRsc04. As a platform company, we really have the opportunity to continuously innovate and bring optionality to how we think about developing our medicines. I think the other point to make, which I think is quite important, is just to remind everybody that Vutrisiran has orphan disease designations for TTR amyloidosis, whether it be polyneuropathy or cardiomyopathy. Many companies, including us, are reflecting on the implications of this relatively new legislation on how we think about our portfolio. But as a company, we think we are very well positioned given our platform and our ability to continue to innovate around our medicines.

Okay. The next question?

Our next question comes from Gary Nachman from BMO. Your line is open.

Hi. Good morning. If you end up getting the ONPATTRO or APOLLO-B approval, let’s say, at the end of next year, but then you will be bumping up against the Vutrisiran HELIOS-B data in early 2024. How much of an impact do you think that might have on your launch of ONPATTRO in cardiomyopathy when physicians may be anticipating this other important data set? I know it’s a bit early thinking about the launches, but given the timing of these, I was curious to get some of your early thoughts on that. Thanks.

Well, I will just start off by saying that the reason why we progress ONPATTRO in the cardiomyopathy indication is the level of unmet medical need; that’s the patients who continue to progress despite various therapies. Really, we took the opportunity with ONPATTRO to try to bring a near-term solution for these patients, while we continue to develop Vutrisiran in our HELIOS-B study. As you pointed out, we will have those results shortly at the beginning of 2024. We think that we are able to meet the needs of patients in the near term, hopefully with the approval of ONPATTRO and CM, and then as we progress HELIOS-B going forward, an even more attractive regimen for these patients shortly afterward. But maybe Tolga, you can comment on how we are thinking about the launch of ONPATTRO with the opportunity of hopefully bringing Vutrisiran to these patients in the medium term.

Yes. No, I think you summarized it perfectly, Yvonne. All I would add is that there is a big unmet need. There are patients who are currently on available treatments that are continuing to progress. To your point, we want to make an alternative treatment available as quickly as possible so we can meet those needs and also continue to build our capabilities for the larger indication. We are obviously very pleased with the capabilities that we have built based on what we are actually able to demonstrate with the AMVUTTRA CM launch. As we continue to expand the indication, we believe our experience with the CM will assist us to have an even stronger launch with AMVUTTRA CM, if it’s approved.

Thanks, Tolga, that’s great. So again, the sort of TTR franchise approach, which we think will be important for patients and our commercial performance going forward.

Next question.

Thank you. Our next question comes from Luca Issi from RBC Capital. Your line is open.

Hey. Great. Thanks so much for taking my question. Maybe one on the pipeline, if I may. Any additional color on why the readout has been pushed out? And maybe bigger picture, can you level set expectations for the next year? What reduction in CSF APP alpha and beta would you consider meaningful? And maybe what’s the earliest we could possibly see functional data for that dataset? Thanks so much.

Great. Thank you, Luca, for a question on APP. Look, we are clearly excited about the potential for RNAi therapeutics addressing CNS diseases. This is the first one out of the gate, and we are progressing very well but thoughtfully, as Akshay described in his introductory remarks. But actually, maybe you can speak to the data that we are expecting after the ongoing study.

Yes. The crucial data, I think first and foremost, is safety. This is our first candidate in the central nervous system. So, that’s a keen interest. The study is progressing well, so we are very comfortable so far. Beyond that, obviously, there is lots of interest in the biomarker outlook. We will be looking for APP knockdown and the fragment therapeutic trail from APP changes in those of the CNS.APP. In addition to that, there are going to be important PK measures because, again, it’s the first time we have injected with that route. Those are the key data points in the short term that we will be looking at and look forward to reporting in early 2023.

Absolutely, and as we move forward in APP, we are able to demonstrate the impact on patients with anyone who has Alzheimer’s disease. The quarter opens up the opportunity for a whole host of other devastating CNS conditions. So, a very important program for us, we are progressing well. Thank you for the question.

Next question please.

Thank you. Our next question comes from Joseph Stringer from Needham & Company. Your line is open.

Hi. Good morning. Thanks for taking our question. A question on AMVUTTRA start forms in the percentage sourced from new prescribers. I think this quarter you have around 17%, that was somewhat similar to 20% from your last update. Do you sort of see this continuing and fairly stable in that 15% to 20% range going forward, or how do you see that going forward? Thank you.

Tolga, that’s clearly a question for you. How do you see the percentage of new prescribers going forward?

Yes. Look, I mean I am glad you have highlighted that. We are really excited about how we are displaying those strong foundational capabilities that we have been able to build from diagnosis all the way to access support. One of those excitements is we see a healthy balance of physicians, both from academic centers and community specialists start prescribing this medication. As you pointed out, another important metric is the new prescribers. We see a steady increase of this new specialist around 20% month-after-month being added to the prescriber base. As a result of that, we also see patients are being treated a bit younger, a sign that patients are getting diagnosed, and obviously, they are getting the AMVUTTRA treatment. Another important metric that we also see, and where we are obviously going to pay a lot of attention to this, is our start forms to treatment rates. Despite having a temporary J-code, it’s been similar to ONPATTRO. Again, thanks to our good access support, VBAs, and our price parity strategy. Because of those elements, we believe we are going to continue to see a good expansion of new prescribers and net new patients for AMVUTTRA that’s going to drive the TTR franchise to the next level.

Super. Thank you very much.

Look, we have had a great quarter. We are really based on our commercial performance, and we are seeing strong growth in patients on therapy across all of our commercial portfolio. So, I am certainly very pleased with our performance. Thank you everyone for joining us on this call. Great progress in the third quarter of 2022. We talked about our strong commercial results, but also we are pleased with how we are advancing our diverse pipeline programs that are in development. A lot of excitement ahead, cashless on deck in the coming months and we, of course, look forward to updating you along the way as we continue to deliver on our near and long-term goals.

Thank you. Ladies and gentlemen, this does conclude today’s conference. Thank you all for participating. You may now disconnect. Have a great day.